Please login to the form below

Not currently logged in
Email:
Password:

rilpivirine

This page shows the latest rilpivirine news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

It combines ViiV’s own Tivicay (dolutegravir) the most widely prescribed integrase inhibitor worldwide, and J&J’s  Edurant (rilpivirine).

Latest news

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    The advisory committee issued a positive opinion for Juluca - which combines ViiV’s integrase inhibitor Tivicay (dolutegravir) with a non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine) developed by Johnson &Johnson’s

  • GSK’s ViiV gets US okay for two-drug HIV regimen GSK’s ViiV gets US okay for two-drug HIV regimen

    The US regulator gave a green light to Juluca, which combines ViiV’s integrase inhibitor Tivicay (dolutegravir) with a non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine) developed by J&J’s ... The company is also testing the

  • ViiV files two-drug HIV maintenance regimen ViiV files two-drug HIV maintenance regimen

    It is also investigating a dual therapy based on integrase inhibitor  cabotegravir and rilpivirine that could be given as a monthly or bi-monthly injection as an alternative to daily doses ... Data from the SWORD studies supported our hypothesis that a

  • ViiV takes two-drug cocktail for first-line HIV into phase III ViiV takes two-drug cocktail for first-line HIV into phase III

    In addition to the Tivicay/Epivir combination, ViiV is also investigating a dual therapy based on integrase inhibitor cabotegravir and Johnson &Johnson's non-nucleoside RTI rilpivirine that could be given ... It also has an oral dolutegravir/rilpivirine

  • Gilead gets EU nod for TAF-based triple therapy for HIV Gilead gets EU nod for TAF-based triple therapy for HIV

    The once-daily, single-tablet combines TAF with emtricitabine - a dual therapy sold as Descovy - with Johnson &Johnson's Edurant (rilpivirine). ... It is a follow up to Gilead's $1.4bn Complera, which contains emtricitabine, rilpivirine and tenofovir

More from news
Approximately 3 fully matching, plus 20 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics